vs
Side-by-side financial comparison of Aeluma, Inc. (ALMU) and Bolt Biotherapeutics, Inc. (BOLT). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.3M, roughly 2.0× Aeluma, Inc.). Aeluma, Inc. runs the higher net margin — -145.7% vs -265.2%, a 119.6% gap on every dollar of revenue.
Aeluma, Inc. is a U.S.-headquartered technology firm focused on the design, development, and production of high-performance optoelectronic components and semiconductor products. Its core offerings include photonic sensors and laser diodes, serving the LiDAR, 5G/6G communication, industrial sensing, and automotive markets across North America and the Asia-Pacific region.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
ALMU vs BOLT — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $2.5M |
| Net Profit | $-1.9M | $-6.6M |
| Gross Margin | 27.8% | — |
| Operating Margin | -163.6% | -283.4% |
| Net Margin | -145.7% | -265.2% |
| Revenue YoY | -21.1% | — |
| Net Profit YoY | 36.0% | 58.4% |
| EPS (diluted) | $-0.11 | $-9.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | $2.5M | ||
| Q3 25 | $1.4M | $2.2M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $1.1M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $5.3M |
| Q4 25 | $-1.9M | $-6.6M | ||
| Q3 25 | $-1.5M | $-7.1M | ||
| Q2 25 | — | $-8.6M | ||
| Q1 25 | — | $-11.0M | ||
| Q4 24 | — | $-15.9M | ||
| Q3 24 | — | $-15.2M | ||
| Q2 24 | — | $-21.2M | ||
| Q1 24 | — | $-10.8M |
| Q4 25 | 27.8% | — | ||
| Q3 25 | 49.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -163.6% | -283.4% | ||
| Q3 25 | -116.1% | -355.1% | ||
| Q2 25 | — | -510.5% | ||
| Q1 25 | — | -991.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1441.1% | ||
| Q2 24 | — | -1772.3% | ||
| Q1 24 | — | -324.1% |
| Q4 25 | -145.7% | -265.2% | ||
| Q3 25 | -107.8% | -329.4% | ||
| Q2 25 | — | -474.6% | ||
| Q1 25 | — | -903.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1330.1% | ||
| Q2 24 | — | -1662.4% | ||
| Q1 24 | — | -205.0% |
| Q4 25 | $-0.11 | $-9.38 | ||
| Q3 25 | $-0.09 | $-3.72 | ||
| Q2 25 | — | $-4.46 | ||
| Q1 25 | — | $-0.29 | ||
| Q4 24 | — | $-13.73 | ||
| Q3 24 | — | $-7.93 | ||
| Q2 24 | — | $-11.12 | ||
| Q1 24 | — | $-0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.6M | $27.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $40.8M | $26.5M |
| Total Assets | $42.6M | $56.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.6M | $27.5M | ||
| Q3 25 | $25.9M | $31.9M | ||
| Q2 25 | — | $34.8M | ||
| Q1 25 | — | $38.8M | ||
| Q4 24 | — | $47.3M | ||
| Q3 24 | — | $53.8M | ||
| Q2 24 | — | $73.7M | ||
| Q1 24 | — | $91.3M |
| Q4 25 | $40.8M | $26.5M | ||
| Q3 25 | $40.9M | $32.1M | ||
| Q2 25 | — | $38.8M | ||
| Q1 25 | — | $46.8M | ||
| Q4 24 | — | $57.2M | ||
| Q3 24 | — | $72.0M | ||
| Q2 24 | — | $85.9M | ||
| Q1 24 | — | $104.2M |
| Q4 25 | $42.6M | $56.7M | ||
| Q3 25 | $42.7M | $65.1M | ||
| Q2 25 | — | $75.5M | ||
| Q1 25 | — | $85.9M | ||
| Q4 24 | — | $99.6M | ||
| Q3 24 | — | $109.3M | ||
| Q2 24 | — | $124.2M | ||
| Q1 24 | — | $142.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-251.0K | $-7.2M |
| Free Cash FlowOCF − Capex | $-282.0K | — |
| FCF MarginFCF / Revenue | -22.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-251.0K | $-7.2M | ||
| Q3 25 | $-815.0K | $-9.7M | ||
| Q2 25 | — | $-9.6M | ||
| Q1 25 | — | $-13.4M | ||
| Q4 24 | — | $-14.4M | ||
| Q3 24 | — | $-14.0M | ||
| Q2 24 | — | $-16.1M | ||
| Q1 24 | — | $-16.8M |
| Q4 25 | $-282.0K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-14.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -22.2% | — | ||
| Q3 25 | -74.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1227.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 15.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
